GLP-1 changed weight loss. Oprimaze solves what GLP-1 leaves behind.
The industry gave people a way to lose weight. But most regain it within a year of stopping. Oprimaze was built around the gap everyone else ignored.
GLP-1 was a breakthrough. The exit from it wasn't.
GLP-1 therapies have transformed weight management — proven, widely prescribed, effective. But the industry built the treatment and ignored the transition. When the therapy ends, the appetite suppression and metabolic recalibration withdraw. The body's adaptive responses — calibrated to restore lost weight — reactivate.
Why GLP-1 alone isn't the full answer.
Nausea & GI side effects
Roughly 44% of users report nausea — the leading reason for early discontinuation.
Injection barrier
Weekly injections aren't a fit for everyone, and adherence drops over time.
Cost & access
£200–500 per month puts ongoing therapy out of reach for many.
No exit pathway
When therapy ends, there's no structured plan for the predictable rebound.
- One product for two distinct phases
- Slow, low-bioavailability oral delivery
- Needles, GI side effects, or stimulants
- No support after the weight comes off
- Two sprays for two distinct phases
- Fast nasal delivery, minutes not hours
- Plant-based actives, clean labels
- A maintenance ritual designed to keep results